Insider buying last 90 days
No open-market insider purchases were filed for VRDN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VRDN insider filing, plotted on the chart in Gekko.Open VRDN in Gekko
NASDAQ: VRDN
Viridian Therapeutics (VRDN) Stock Analysis & Forecast
Oct 12 close
$18.30−0.36 (−1.9%)
Gekko Brief
AI summaryOct 12 closeRBC Capital reiterated its Buy rating on Viridian Therapeutics this week, maintaining a price target of $38.00, following an earlier Buy rating from LifeSci Capital. The reiteration follows the company's reported Q2 revenue of $284 thousand and a GAAP net loss of $127.12 million.
VRDN closed at $18.30, down 1.9% on the day, with the one-month return at -13.8% and the six-month return at 23.6%. The stock sits below both its 50-day average of $21.83 and its 200-day average of $22.42, with the 50-day below the 200-day. The GekkoIndex reads 68.3, placing VRDN in the Accumulation zone, and the price stands 33.1% below the Gekko Fair Value of $27.34.
Over the next 20 trading days, the main event is the earnings report scheduled for 4 November 2026, 23 days away, which falls inside a typical holding window; the last report, on 6 August 2026, produced a 12% reaction versus an average absolute move of 10.5% across prior quarters, with 4 beats out of 8. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged +11.7% over 5 years, rising in 4 of them, a pattern worth noting given the stock's typical 20-day move of 11.6%. Analyst consensus from 11 firms remains Buy, with a consensus target of $36.75.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Viridian Therapeutics price vs fair value
Close $18.30200-day averageGekko Fair Value $27.34
Viridian Therapeutics quick facts
- Market cap
- $2.07B
- P/E ratio
- —
- Forward P/E
- 1
- EPS, TTM
- −$3.39
- Revenue, TTM
- $71.13M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.10
- Volume
- 1.95M avg 2.04M
- 1-year return
- −16.1%
- Typical daily move
- ±5%
- Typical 20-day move
- ±11.6%
- 50-day average
- $21.83
- 200-day average
- $22.42
- Next earnings
- Nov 4
- Shares outstanding
- 113.3M
Viridian Therapeutics swing-trade checklist
Viridian Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $18.30 is below the 50-day ($21.83) and 200-day ($22.42) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
68.3, Accumulation
Reading 68.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
33.1% below
Price is 33.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+11.7% on average
From this point in the calendar, the next 20 trading days averaged +11.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Viridian Therapeutics stock chart and price history
Viridian Therapeutics closed at $18.30 on Oct 12, 2026, −16.1% over the past year, inside a 52-week range of $13.18 to $34.29.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.8%
- 3 months
- −4.1%
- 6 months
- +23.6%
- 1 year
- −16.1%
The full VRDN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VRDN in Gekko
Follow Viridian Therapeutics through every session
Put VRDN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VRDN in GekkoFree for 7 days. No credit card required.
About Viridian Therapeutics
Viridian Therapeutics works on treatments for people facing serious medical conditions, with its efforts centered on thyroid eye disease. Its lead candidate, VRDN-001, is a humanized monoclonal antibody targeting IGF-1R, now being tested in Phase 1/2 trials. The company is best known for this program as it works to address TED through antibody-based therapies.
Beyond its lead candidate, Viridian Therapeutics is advancing a pipeline of related compounds. VRDN-002, another antibody aimed at IGF-1R, is in Phase 1 evaluation, while VRDN-003 similarly targets IGF-1R as a therapeutic approach for thyroid eye disease. Together these programs reflect the company's focus on a shared biological target across multiple drug candidates still in early clinical stages.
The company traces its origins to 2006 and is headquartered in Waltham, Massachusetts. It operated under the name Miragen Therapeutics before adopting its current name, Viridian Therapeutics, in January 2021. Shares of the company are listed on the NASDAQ under the ticker VRDN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- viridiantherapeutics.com
Viridian Therapeutics GekkoIndex: the smart money zone
Viridian Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.3, in the Accumulation zone, down 1.7 points over five sessions.
68.3Accumulation
Down 1.7 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 50 | −0.2% | −0.3% | ||
| Accumulation (current zone) | 249 | +0.4% | −1.9% | ||
| Neutral | 342 | +0.6% | +4.5% | ||
| Distribution | 38 | −0.5% | +4.3% | ||
| Selling | 3 | Too few readings yet | |||
Average VRDN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the VRDN price, zone by zone.Track VRDN in Gekko
Is Viridian Therapeutics stock overvalued? Gekko Fair Value
Viridian Therapeutics trades 33.1% below Gekko Fair Value of $27.34, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Viridian Therapeutics shares are worth, recalculated every trading day.
$27.34
Gekko Fair Value, Oct 10, 2026
33.1% Undervalued
At the end of Aug 2026 the price was 25.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VRDN in Gekko
Viridian Therapeutics insider and Congress trading
No open-market insider purchases were filed for Viridian Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VRDN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VRDN, plotted on the chart in Gekko.Open VRDN in Gekko
Buybacks
Viridian Therapeutics has been buying back its own shares.
- Bought back, year ended Dec 31, 2016
- $173K
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold VRDN.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Viridian Therapeutics earnings: next date and track record
Viridian Therapeutics reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- −$0.97
- Revenue estimate
- $4.58M
4 of 8reports beat the EPS estimate
±10.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$1.05 est −$1.03 | $284K est $56K | +12.0% |
| May 5, 2026 | −$0.90 est −$1.08 | $141K est $36K | +24.7% |
| Feb 26, 2026 | −$1.08 est −$0.90 | $132K est $18.38M | +1.5% |
| Nov 5, 2025 | −$0.34 est −$0.82 | $70.57M est $15.75M | +22.0% |
| Aug 6, 2025 | −$1.00 est −$1.00 | $75K | −5.2% |
| May 6, 2025 | −$0.87 est −$0.95 | $72K est $44K | −6.3% |
| Feb 27, 2025 | −$0.81 est −$1.04 | $72K est $50K | 0.0% |
| Nov 12, 2024 | −$1.15 est −$1.05 | $86K est $50K | −12.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Viridian Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Viridian Therapeutics is $36.75, +100.8% from the last close, from 11 firms rating the stock in the last 90 days.
$36.75consensus 12-month target, +100.8% from the last close
Now $18.30Avg $36.75
Low $22High $41
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | RBC Capital | $38 | +107.7% |
| Oct 2 | LifeSci Capital | $35 | +91.3% |
| Sep 22 | RBC Capital | $38 | +107.7% |
| Sep 1 | Truist Financial | — | — |
| Aug 13 | Stifel Nicolaus | $40 | +118.6% |
−1.9%average 20-day move after past Accumulation readings
+11.7%average move over the next 20 trading days in the last 5 years
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Viridian Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Viridian Therapeutics averaged +11.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.9% | 4 of 5 |
| Next 10 trading days | −0.5% | 3 of 5 |
| Next 15 trading days | +3.6% | 3 of 5 |
| Next 20 trading days | +11.7% | 4 of 5 |
| Next 30 trading days | +16.9% | 4 of 5 |
For scale, VRDN’s typical 20-trading-day move in either direction is about 11.6%.
Viridian Therapeutics market cap and key statistics
Viridian Therapeutics’s market cap is $2.07B and revenue of $71.13M over the last twelve months.
Valuation
- Market cap
- $2.07B
- Forward P/E
- 1
- EPS, TTM
- −$3.39
- Gekko Fair Value
- $27.34
Trading
- Volume
- 1.95M
- Avg volume, 20 days
- 2.04M
- 52-week high
- $34.29
- 52-week low
- $13.18
- Shares outstanding
- 113.3M
Financials
- Revenue, TTM
- $71.13M
- Profit margin
- 0%
- Return on equity
- -65.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.10
- Typical daily move
- ±5%
- Typical 20-day move
- ±11.6%
Viridian Therapeutics stock news this week
2 headlines about Viridian Therapeutics from the past week, newest first, each linking to the publisher.
Viridian Therapeutics peers
Viridian Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Viridian Therapeutics stock FAQ
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $2.07B at the Oct 12, 2026 close of $18.30, with 113.3M shares outstanding.
What is the Viridian Therapeutics stock forecast?
The consensus analyst 12-month price target for Viridian Therapeutics is $36.75, +100.8% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Viridian Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Viridian Therapeutics is undervalued: the Oct 12, 2026 close of $18.30 is 33.1% below Gekko Fair Value of $27.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Viridian Therapeutics report earnings next?
Viridian Therapeutics is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of −$0.97 per share on revenue of $4.58M. Viridian Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 10.5% on average across the report.
What is Viridian Therapeutics’s 52-week high and low?
Viridian Therapeutics’s 52-week high is $34.29 and its 52-week low is $13.18; it closed at $18.30 on Oct 12, 2026, −16.1% over the past year. Over the last five years the shares peaked at $39.00 on Jan 25, 2023.
Is Viridian Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Viridian Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.